Spread the love

A recent study from the Mammalian Genetics Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom; and School of Medicine, King’s College London, London, United Kingdom shows that “Loss of Fbw7 Reprograms Adult Pancreatic Ductal Cells into α, δ, and β Cells.” This study was published in the August 7  2014 Cell Stem Cell (Number1 journal in Regenerative Medicine with an I.F of ~25) by Prof Axel Behrens, Rocio Sancho, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Regenerative therapy for DM: β-Catenin/CTNNB1 promotes  reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up regulation of Ngn3. This study suggests that β-Catenin/CTNNB1by increasing the expression of Ngn3 in adult pancreatic ductal cells, it may reprogram adult pancreatic ductal cells into β cells.  Thereby, it may induce the expression of Ngn3increase insulin secretion and inhibit insulin resistance. Together, this study suggests that pharmacological formulations encompassing β-Catenin/CTNNB1 or its activators” may be used to regenerate  β cells in DM patients. 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Regenerative therapy for DM: β-Catenin/CTNNB1 promotes  reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up regulation of Ngn3, 8/October/2014, 5.44 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Spread the love